StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences SBC expense — Research and development by Year

SBC expense — Research and development ($M) ($M)

Gilead Sciences SBC expense — Research and development: $433M in FY2025, down 5.5% from a year earlier.

Latest, FY2025
433
Period ended Dec 31, 2025
Change on a year earlier
-5.5%
458 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Note 13 Stock-Based Compensation.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSBC expense — Research and development ($M) ($M)Year on yearSource
FY2025Dec 31, 2025433-5.5%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 2024458+21.5%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023377+32.3%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 2022285-0.7%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 2021287-37.9%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 2020462+59.9%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 2019289-23.7%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 2018379+63.4%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 2017232+31.8%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 2016176+1.7%Form 10-K (filed 2019-02-26) ↗
FY2015Dec 31, 2015173+13.8%Form 10-K (filed 2018-02-27) ↗
FY2014Dec 31, 2014152–Form 10-K (filed 2017-02-27) ↗

Cite this data

StockData. (2026). Gilead Sciences SBC expense — Research and development ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/sbc-rd

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.